Annual reportSep 2026
Sep 2026 · Reg. 34 (1) Annual Report. 28 Aug - Submitted FY2025-26 annual report; 89th AGM on 23 Sept 2026; final dividend ₹2.90 per share.
Source: Bse
Amrutanjan Health Care Limited (AMRUTANJAN)
Small CapConsumer stocks · Small cap · NSE
Amrutanjan Health Care Limited operates in OTC Products, within the Consumer sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result16 Aug, 12:57 am IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags03 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Consumer P/E 22.2 (n=441)
Technical timing lens
Trend score and candlestick chart
39BearishMACD − · near 52W low · sector -3.7pp vs Nifty 500 (3M)
Stock trend: 41
Sector RS: 36
Sector 3M: -9.3% vs Nifty 500 -5.6%
Consumer FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
AMRUTANJAND candles · FIT view-13.4%Latest close ₹499.15 on 2026-10-19
Bar
-3.4%
RSI
45
MACD hist
-0.62
52W pos
8%
2026-10-19O ₹516.95H ₹516.95L ₹496.65C ₹499.15Vol 26,870 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
AMRUTANJANNifty Consumer DurablesNifty 500
- AMRUTANJAN
- -8.7%
- Nifty 500
- -5.6%
- Nifty Consumer Durables
- -9.7%
- Vs Nifty 500
- -3.1 pp
Chart stats
19 Oct 2026- From 52W high
- -34.3%
- 52W range position
- 8%
- ATR (14)
- 2.8%
- Volume vs 20D
- 0.77x
- Avg traded value
- ₹1.8 Cr
- 20D price channel
- ₹490 - ₹527
₹760.2
₹476.5 - ₹760.2
₹14.2
Latest completed session
20-session average
23.5% annualized volatility
Research snapshot
What the evidence says now
Mixed fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend argues for patience, and recent execution is mixed.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · FAIR VALUE52
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad0
Revenue +9.5% · PAT -47.4% YoY
Technical
Bearish39
Price trend and sector-relative-strength timing.
Valuation
Legacy model-112.6%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence81
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 0/100PAT -47% YoY · margin compression · Rev +9% YoY
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹103 Cr | +9.5% | -31.3% |
| EBITDA | ₹6.2 Cr | -26.1% | -75.6% |
| Operating margin | 6.1% | -291 bps | -1100 bps |
| PAT | ₹4.4 Cr | -47.4% | -73.0% |
| PAT margin | 4.2% | -460 bps | -657 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 73.40
- P/B
- 13.92
- EV/EBITDA
- 44.06
- Market Cap
- 1496.00Cr
Profitability
- ROE
- 20.00%
- ROCE
- 31.40%
- ROA
- 15.00%
- Dividend Y
- 0.95%
Growth (CAGR)
- Revenue 5Y
- 12.00%
- EPS 5Y
- 15.00%
- Revenue 3Y
- 11.00%
- EPS 3Y
- 27.00%
Balance Sheet
- Debt/Equity
- 0.02
- Interest Coverage
- —
- Altman Z
- 9.34
- Book Value
- 37.20
Cash Flow
- FCF Yield
- 1.67%
- FCF Positive Y
- 8/5
- OCF
- 21.00 Cr
- EPS TTM
- 7.05
Shareholding
- Promoter Hold
- 46.52%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 15%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 503+11.3% vs prev
Net Profit
₹ CrLatest: 58.0+13.7% vs prev
Return on Equity
%Latest: 15.7+0.5% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term trend down. RSI 45.
- Price below SMA200 (long-term downtrend) — short-term bounces likely countertrend.
- SMA20 roughly flat — short-term momentum stalled.
- RSI(14) at 45 — sideways, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- Within 5% of 52-week low — testing support.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
27
RS percentile
Stage 4 Downtrend
1M return
+1.1%
3M return
-8.7%
6M return
-12.6%
1Y return
-32.7%
RS 1D
-4
RS 20D
+6
Sector rank
#9
Industry rank
-
Stage evidence
- Price is 5.8% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -1.4%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
neutral
Industry
unranked
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 70.92-1.84%
RS vs Nifty 50071
Valuation & peers
U-Score 52 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Valuation & peers
U-Score 52 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Premium Compounder
Fundamental score breakdown
U band · FAIR VALUEValuation0/30
Growth14/25
Quality17/20
Balance Sheet8/15
Cash Flow7/10
Piotroski
7/9 (+5)
Penalties
1
Raw sum
52
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
52/100 · legacy band FAIR VALUE
Positive drivers
- Piotroski is strong at 7/9.
- Quality contributes 17/20 to the score.
- Cash flow contributes 7/10 to the score.
Main drags
- Fair-value margin of safety is negative at -112.6%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
- Balance sheet is weaker at 8/15; verify the latest quarterly trend.
Sector valuation model
Consumer valuation: PE/PEG and brand-quality premium
Consumer franchises can deserve higher multiples, but only when growth quality supports them.
Primary lens
PE and PEG relative to growth, ROE, margins, and brand strength.
Secondary checks
Volume growth, pricing power, distribution, same-store or category growth.
Main risk check
Premium valuation needs durable growth and margin resilience.
PE
73.4
PB
13.9
EV/EBITDA
44.1
ROE
20.0%
ROCE
31.4%
FCF Yield
1.7%
Debt/Equity
0.0
MoS
-112.6%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
52
Previous: 52
Legacy U-Score band
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
-112.6%
Previous: -112.6%
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
52
52
52
52
52
52
52
52
52
52
52
52
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹76.82
-549.8% MoS
Growth-justified P/E
33.3
Growth-justified Value
₹234.77
-112.6% MoS
PEG
3.71
Comparable companies
Peers
Business-comparable peers in Consumer — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
KAYA
Small
Kaya Limited
Consumer Healthcare
match 116
11
—
—
—
OVERVALUED
WALPAR
SME
Walpar Nutritions Ltd.
Consumer Healthcare
match 109
64
9.9
13.9%
+78%
UNDERVALUED
MHHL
SME
Mohini Health & Hygiene Ltd.
Consumer Healthcare
match 108
18
—
-8.9%
—
OVERVALUED
PGHL
Small
Procter & Gamble Health Limited
Pharmaceuticals
match 94
53
26.7
61.9%
-94%
FAIR VALUE
ASIANHOTNR
Small
Asian Hotels (North) Limited
Hospitality
match 91
26
106.0
0.6%
-218%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Amrutanjan Health Care Limited operates in OTC Products, within the Consumer sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
81Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 93rd percentile of the scored universe and 96th percentile within Consumer. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
58 docs text-extracted · 1 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
93rd percentile
overall median 67 · Consumer: 96th pctile, median 66 · Small: 95th pctile, median 66
Evidence depth
Financial-only
58 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
88
strong · leverage and solvency
Discipline
90
strong · capital discipline
Results
72
acceptable · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 1%.
- ▸12 years of positive FCF.
- ▸Debt/equity is 0.01.
Trust risks
- ▸1 of the latest 4 quarters had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Amrutanjan Health Care Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Investor presentationAug 2026
Aug 2026 · PPT
Source: Bse
Credit rating
Additional Details Required For Corporate Announcement Filed Under Regulation 30 Of SEBI (LODR) Regulations, 2015, 6 Aug - Amrutanjan explains delay in Regulation 30 credit rating intimation; seeks condonation.
Source: Bse
Investor presentationMay 2026
May 2026 · PPT
Source: Bse
AnnouncementMay 2026
May 2026 · Announcement under Regulation 30 (LODR)-Change in Management 26 May - Mr. Raja Venkataraman ceased as Independent Director on 26 May 2026 after completing first term.
Source: Bse
Investor presentationMay 2026
May 2026 · PPT
Source: Bse
AnnouncementMay 2026
May 2026 · Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 19 May
Source: Bse
Annual reportMar 2026
Mar 2026 · Annual Report 2026
Source: Bse
Investor presentationFeb 2026
Feb 2026 · PPT
Source: Bse
Investor presentationFeb 2026
Feb 2026 · PPT
Source: Bse
Investor presentationNov 2025
Nov 2025 · PPT
Source: Bse
Investor presentationNov 2025
Nov 2025 · PPT
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.